He Xiaoning, Zhang Mengqian, Wu Jing, Xu Song, Jiang Xiangli, Wang Ziping, Zhang Shucai, Xie Feng
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People's Republic of China.
Center for Social Science Survey and Data, Tianjin University, Tianjin, People's Republic of China.
Patient Prefer Adherence. 2021 Apr 15;15:775-783. doi: 10.2147/PPA.S299399. eCollection 2021.
Cancer treatment decision-making often needs to balance benefits, harms, and costs. This study sought to identify the differences in cancer treatment preference among oncologists, patients and their family members in China.
A semi-structured face-to-face qualitative interview was conducted among oncologists, patients and their family members recruited in four tertiary hospitals in China. The interview guide was developed based on literature review and expert consultation. Participants were asked to indicate their preferences when making lung cancer treatment decisions. All interviews were audio-taped, transcribed verbatim, and thematic analyzed. The preferences were compared among three groups of participants.
A total of 17 participants (5 oncologists, 6 dyads of patients and family members) were interviewed between June and July 2019. Five themes, namely, survival benefit, adverse effect/symptom, treatment process, treatment cost, and the impact on daily life were identified. The oncologists and family members gave highest priority on survival benefit, while the patients are concerned most about treatment cost and quality of life.
This study reveals different preferences for cancer treatment among oncologists, patients and their family members in China. Education is needed to empower patients and family members and promote share decision-making in this country.
癌症治疗决策通常需要在获益、危害和成本之间取得平衡。本研究旨在确定中国肿瘤学家、患者及其家属在癌症治疗偏好上的差异。
对在中国四家三级医院招募的肿瘤学家、患者及其家属进行了半结构化面对面定性访谈。访谈指南是在文献综述和专家咨询的基础上制定的。参与者被要求在做出肺癌治疗决策时表明他们的偏好。所有访谈都进行了录音、逐字转录并进行了主题分析。比较了三组参与者的偏好。
2019年6月至7月期间共访谈了17名参与者(5名肿瘤学家、6对患者及其家属)。确定了五个主题,即生存获益、不良反应/症状、治疗过程、治疗成本以及对日常生活的影响。肿瘤学家和家属最优先考虑生存获益,而患者最关心治疗成本和生活质量。
本研究揭示了中国肿瘤学家、患者及其家属在癌症治疗上的不同偏好。需要开展教育,增强患者及其家属的能力,并在该国促进共同决策。